These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 36277502

  • 1. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB, Pergola P.
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E, White WB, Bakris G.
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R, Xu L, Che L, Liu S, Wang Y, Dong B.
    Front Endocrinol (Lausanne); 2023 Apr; 14():1125693. PubMed ID: 36860374
    [Abstract] [Full Text] [Related]

  • 4. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ.
    Curr Diab Rep; 2019 Jan 23; 19(1):4. PubMed ID: 30673886
    [Abstract] [Full Text] [Related]

  • 5. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
    Shah M, Awad AS, Abdel-Rahman EM.
    J Clin Med; 2023 Sep 29; 12(19):. PubMed ID: 37834929
    [Abstract] [Full Text] [Related]

  • 6. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M.
    Circulation; 2024 Feb 06; 149(6):450-462. PubMed ID: 37952217
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
    Palanisamy S, Funes Hernandez M, Chang TI, Mahaffey KW.
    Cardiol Ther; 2022 Sep 06; 11(3):337-354. PubMed ID: 35737275
    [Abstract] [Full Text] [Related]

  • 8. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B, FIGARO-DKD Investigators.
    Circulation; 2022 Feb 08; 145(6):437-447. PubMed ID: 34775784
    [Abstract] [Full Text] [Related]

  • 9. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
    Morales J, Palmer BF.
    Postgrad Med; 2024 Mar 08; 136(2):111-119. PubMed ID: 38344772
    [Abstract] [Full Text] [Related]

  • 10. Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
    Singh AK, Singh R.
    World J Diabetes; 2022 Jul 15; 13(7):471-481. PubMed ID: 36051422
    [Abstract] [Full Text] [Related]

  • 11. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
    Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Wanner C, Joseph A, Scheerer MF, Scott C, Bakris GL, FIDELIO-DKD Investigators.
    Kidney Int Rep; 2022 Jan 15; 7(1):36-45. PubMed ID: 35005312
    [Abstract] [Full Text] [Related]

  • 12. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F, Montini G, Kang HG, Walle JV, Zaritsky J, Schreuder MF, Litwin M, Scalise A, Scott H, Potts J, Iveli P, Breitenstein S, Warady BA.
    Trials; 2024 Mar 21; 25(1):203. PubMed ID: 38509517
    [Abstract] [Full Text] [Related]

  • 13. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL.
    Nephrol Dial Transplant; 2022 Jun 23; 37(7):1261-1269. PubMed ID: 34850173
    [Abstract] [Full Text] [Related]

  • 14. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL, Lee SE, Kim NH.
    Endocrinol Metab (Seoul); 2023 Feb 23; 38(1):43-55. PubMed ID: 36891650
    [Abstract] [Full Text] [Related]

  • 15. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L.
    Ann Med; 2023 Dec 23; 55(1):502-513. PubMed ID: 36719097
    [Abstract] [Full Text] [Related]

  • 16. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M.
    Am J Nephrol; 2021 Dec 23; 52(3):209-216. PubMed ID: 33857953
    [Abstract] [Full Text] [Related]

  • 17. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R.
    JACC Heart Fail; 2022 Nov 23; 10(11):860-870. PubMed ID: 36328655
    [Abstract] [Full Text] [Related]

  • 18. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Nov 23; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 19. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
    Georgianos PI, Agarwal R.
    Am J Hypertens; 2023 Feb 24; 36(3):135-143. PubMed ID: 36331811
    [Abstract] [Full Text] [Related]

  • 20. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H.
    Herz; 2022 Oct 24; 47(5):401-409. PubMed ID: 36094559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.